Sleep, Sleep Disorder, Sleep Disturbance
Conditions
Brief summary
A randomized, blinded, placebo-controlled direct-to-consumer study assessing the impact of health and wellness products on sleep and other health outcomes.
Detailed description
This is a randomized, blinded, placebo-controlled study conducted with adult participants, age 21 and older and residing in the United States. Eligible participants will (1) endorse a desire for improved sleep, (2) indicate an interest in taking a health and wellness product to potentially help their sleep, and (3) express acceptance in taking a product and not knowing its formulation until the end of the study. Participants with known liver or kidney disease, heavy drinkers, and those who report they are pregnant, trying to become pregnant, or breastfeeding will be excluded. Those taking certain medications will be excluded. Self-reported data are collected electronically from eligible participants over 7 weeks. Participant reports of health indicators will be collected during baseline, throughout the active period of study product use, and in a final survey. All study assessments will be electronic; there are no in-person visits or assessments for this real-world evidence study.
Interventions
DIETARY_SUPPLEMENTPlacebo Control Form 2
Participants will use Placebo Control Form 2 as directed for a period of 6 weeks.
DIETARY_SUPPLEMENTRest Study Active Product 1.1 Usage
Participants will use Radicle Rest Active Product 1.1 as directed for a period of 6 weeks.
DIETARY_SUPPLEMENTRest Study Active Product 1.2 Usage
Participants will use Radicle Rest Active Product 1.2 as directed for a period of 6 weeks.
DIETARY_SUPPLEMENTRest Study Active Product 2.1 Usage
Participants will use Radicle Rest Active Product 2.1 as directed for a period of 6 weeks.
DIETARY_SUPPLEMENTRest Study Active Product 2.2 Usage
Participants will use Radicle Rest Active Product 2.2 as directed for a period of 6 weeks.
DIETARY_SUPPLEMENTPlacebo Control Form 1
Participants will use Placebo Control Form 1 as directed for a period of 6 weeks.
DIETARY_SUPPLEMENTPlacebo Control Form 3
Participants will use Placebo Control Form 3 as directed for a period of 6 weeks.
DIETARY_SUPPLEMENTRest Study Active Product 3.1 Usage
Participants will use Radicle Rest Active Product 3.1 as directed for a period of 6 weeks.
DIETARY_SUPPLEMENTPlacebo Control Form 4
Participants will use Placebo Control Form 4 as directed for a period of 6 weeks.
DIETARY_SUPPLEMENTRest Study Active Product 4.1 Usage
Participants will use Radicle Rest Active Product 4.1 as directed for a period of 6 weeks.
DIETARY_SUPPLEMENTRest Study Active Product 4.2 Usage
Participants will use Radicle Rest Active Product 4.2 as directed for a period of 6 weeks.
DIETARY_SUPPLEMENTRest Study Active Product 4.3 Usage
Participants will use Radicle Rest Active Product 4.3 as directed for a period of 6 weeks.
Sponsors
Radicle Science
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Investigator)
Masking description
The investigator is blinded to the participants' study product assignment. Participants are blinded to the study product they are assigned.
Intervention model description
Participants will be stratified based on sex at birth then randomized to one of the study arms
Eligibility
Sex/Gender
ALL
Age
21 Years to 105 Years
Healthy volunteers
Yes
Inclusion criteria
* Adults, 21 years of age and older at the time of electronic consent, inclusive of all ethnicities, races, genders and/or gender identities * Resides in the United States * Endorses better sleep as a primary desire * Selects sleep, looking to improve their sleep, and/or reduce reliance on medications as a reason for their interest in taking a health and wellness product * Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study
Exclusion criteria
* Reports being pregnant, trying to become pregnant, or breastfeeding * Unable to provide a valid US shipping address * The calculated validated health survey (PRO) measurement result is less than mild severity/impairment * Reports a diagnosis of liver or kidney disease * Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day) * Unable to read and understand English * Reports current enrollment in a clinical trial * Lack of reliable daily access to the internet * Reports current or recent (within 3 months) use of chemotherapy, immunotherapy, or oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection * Reports taking medications with a known moderate or severe interaction with any of the active ingredients studied: anticoagulants, a medication that warns against grapefruit consumption, corticosteroids at doses greater than 5 mgs per day, or monoamine oxidase inhibitors (MAOIs) * Reports a diagnosis of heart disease when a known contraindication exists for any of the active ingredients studied: New York Heart Association (NYHA) Class III or IV congestive heart failure, Atrial fibrillation, Uncontrolled arrhythmias
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in sleep disturbance | 6 weeks | Mean difference in sleep disturbance score as assessed by Patient Reported Outcome Measurement System (PROMIS) Sleep Disturbance Short Form 8A (scale 8-40; where higher scores correspond to greater sleep disturbance) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in fatigue | 6 weeks | Mean difference in fatigue score as assessed by PROMIS Fatigue 4A (scale 4-20; where higher scores correspond to more severe fatigue) |
| Change in cognitive function | 6 weeks | Mean difference in cognitive function score as assessed by PROMIS Cognitive Function 4A (scale 4-20; where higher scores correspond to greater cognitive function) |
| Change in anxiety | 6 weeks | Mean difference in anxiety score as assessed by PROMIS Anxiety 4A (scale 4-20; with higher scores corresponding to more severe anxiety) |
| Change in mood (emotional distress) | 6 weeks | Mean difference in mood score as assessed by PROMIS Depression 4A (scale 4-20; where higher scores correspond to more severe depression) |
| Change in libido | 6 weeks | Mean difference in libido score as assessed by PROMIS Sexual Interest 2.0 (scale 2-10; where higher scores correspond to greater sexual interest) |
| Minimal clinical importance difference (MCID) in sleep disturbance | 6 weeks | Likelihood of achieving a MCID in sleep disturbance, as measured by PROMIS Sleep Disturbance Short Form 8A (scale 8-40; where higher scores correspond to greater sleep disturbance) |
Countries
United States
Outcome results
None listed